Pharmaceutical

How a digital biomarker study failed, Apple’s health updates, and Carbon’s AI-driven EHR

How a digital biomarker study failed, Apple’s health up...

Jun 6, 2023

In the latest edition of STAT's Health Tech newsletter: How a digital biomarker ...

Kid EDV by ImmunityBio for Pediatric Diffuse Intrinsic ...

Jun 5, 2023

Kid EDV is under clinical development by ImmunityBio and currently in Phase I fo...

OCX-063 by OccuRx for Proliferative Vitreoretinopathy (...

Jun 5, 2023

OCX-063 is under clinical development by OccuRx and currently in Phase I for Pro...

Izokibep by Acelyrin for Panuveitis: Likelihood of Appr...

Jun 5, 2023

Izokibep is under clinical development by Acelyrin and currently in Phase II for...

Pralsetinib by F. Hoffmann-La Roche for Pancreatic Canc...

Jun 5, 2023

Pralsetinib is under clinical development by F. Hoffmann-La Roche and currently ...

Rezvilutamide by Jiangsu Hengrui Medicine for Prostate ...

Jun 5, 2023

Rezvilutamide is under clinical development by Jiangsu Hengrui Medicine and curr...

Selvita and the University of Oxford join forces to tackle Parkinson’s disease

Selvita and the University of Oxford join forces to tac...

Jun 5, 2023

The collaboration centres on developing protein degraders that could provide an ...

ASCO 2023: Summit Therapeutics plans to rise with bispecific NSCLC data

ASCO 2023: Summit Therapeutics plans to rise with bispe...

Jun 5, 2023

Recent trial data with ivonescimab indicates the treatment could be a much-neede...

ASCO 2023: Research backs chemo-only approach for some rectal cancer patients

ASCO 2023: Research backs chemo-only approach for some ...

Jun 5, 2023

These results could mean some patients may respond adequately to FOLFOX and can ...

ITM raises $273 million to fund radionuclide therapy pipeline

ITM raises $273 million to fund radionuclide therapy pi...

Jun 5, 2023

Described as one of the largest rounds in Germany, the funding will power pipeli...

Rezvilutamide by Jiangsu Hengrui Medicine for Liver Fai...

Jun 5, 2023

Rezvilutamide is under clinical development by Jiangsu Hengrui Medicine and curr...

STAT+: Nuance’s mysterious pricing, speedier digital health evidence reviews, and new breakthrough devices

STAT+: Nuance’s mysterious pricing, speedier digital he...

Jun 4, 2023

In the latest edition of STAT's Health Tech newsletter: Nuance's mysterious pric...

STAT+: Insurance alone didn’t guarantee adherence to Ozempic, study finds

STAT+: Insurance alone didn’t guarantee adherence to Oz...

Jun 4, 2023

A study of thousands of people who were prescribed GLP-based drugs like Ozempic ...

STAT+: Medicare holds firm on Alzheimer’s drug coverage policy

STAT+: Medicare holds firm on Alzheimer’s drug coverage...

Jun 4, 2023

Despite pressure from Congress and advocates, CMS isn’t changing its coverage pl...

STAT+: Biotechs face challenges as the industry’s annual bash returns to Boston

STAT+: Biotechs face challenges as the industry’s annua...

Jun 4, 2023

As the biotech bash BIO 2023 opens tomorrow, industry leaders are bracing for to...

STAT+: ‘Extraordinary’ survival data for lung cancer patients is seen as boost for AstraZeneca drug

STAT+: ‘Extraordinary’ survival data for lung cancer pa...

Jun 4, 2023

“I believe we are curing the cancer by using these best drugs early,” said the l...